Anyone who thought Gilead Sciences Inc. had the hepatitis C virus (HCV) market sewn up with the December 2013 FDA approval of once-daily oral nucleotide analogue sofosbuvir, branded Sovaldi, isn’t taking the long view. Sovaldi is off to a roaring start but, as Leerink Partners LLC analyst Howard Liang observed in a recent HCV industry update, “by our count there are a total of 19 interferon (IFN)-free regimens for which some sustained virological response (SVR, viral cure) data are available.”